Obesity and thyroid cancer risk.
Journal
Current opinion in endocrinology, diabetes, and obesity
ISSN: 1752-2978
Titre abrégé: Curr Opin Endocrinol Diabetes Obes
Pays: England
ID NLM: 101308636
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
medline:
11
9
2023
pubmed:
6
7
2023
entrez:
6
7
2023
Statut:
ppublish
Résumé
This review explores recent evidence assessing the relationship between obesity and thyroid cancer. Consistent evidence from observational studies suggests that obesity increases the risk of thyroid cancer. The relationship persists when alternative measures of adiposity are used, but the strength of association may vary according to the timing and duration of obesity and how obesity or other metabolic parameters are defined as exposures. Recent studies have reported an association between obesity and thyroid cancers that are larger or have adverse clinicopathologic features, including those with BRAF mutations, thus providing evidence that the association is relevant for clinically significant thyroid cancers. The underlying mechanism for the association remains uncertain but may be driven by disruption in adipokines and growth-signaling pathways. Obesity is associated with an increased risk of thyroid cancer, although further research is required to understand the biological mechanisms underpinning this relationship. Reducing the prevalence of obesity is predicted to lessen the future burden of thyroid cancer. However, the presence of obesity does not impact current recommendations for screening or management of thyroid cancer.
Identifiants
pubmed: 37410455
doi: 10.1097/MED.0000000000000825
pii: 01266029-990000000-00066
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
244-251Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Zhai M, Zhang D, Long J, et al. The global burden of thyroid cancer and its attributable risk factor in 195 countries and territories: a systematic analysis for the Global Burden of Disease Study. Cancer Med 2021; 10:4542–4554.
Pandeya N, McLeod DS, Balasubramaniam K, et al. Increasing thyroid cancer incidence in Queensland, Australia 1982-2008 - true increase or overdiagnosis? Clin Endocrinol (Oxf) 2016; 84:257–264.
Megwalu UC, Moon PK. Thyroid cancer incidence and mortality trends in the United States: 2000-2018. Thyroid 2022; 32:560–570.
Arnold M LF, Ervik M, Soerjomataram I. Cancer and Obesity: Global burden of cancer attributable to excess weight. Lyon, France: International Agency for Research on Cancer. 2015 [Available from: Available from: http://gco.iarc.fr/obesity , accessed 02/03/2023.
Feletto E, Kohar A, Mizrahi D, et al. An ecological study of obesity-related cancer incidence trends in Australia from 1983 to 2017. Lancet Reg Health West Pac 2022; 29:100575.
World Health Organization Western Pacific Region. The Asia-Pacific Perspective: Redefining obesity and its treatment. Feb 2000. Available at https://apps.who.int/iris/bitstream/handle/10665/206936/0957708211_eng.pdf?sequence=1&is . [Accessed June 2023]
Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer--viewpoint of the IARC working group. N Engl J Med 2016; 375:794–798.
Kitahara CM, McCullough ML, Franceschi S, et al. Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies. Thyroid 2016; 26:306–318.
Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569–578.
Kitahara CM, Platz EA, Freeman LE, et al. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev 2011; 20:464–472.
Zhao ZG, Guo XG, Ba CX, et al. Overweight, obesity and thyroid cancer risk: a meta-analysis of cohort studies. J Int Med Res 2012; 40:2041–2050.
Ma J, Huang M, Wang L, et al. Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies. Med Sci Monit 2015; 21:283–291.
Schmid D, Ricci C, Behrens G, et al. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obes Rev 2015; 16:1042–1054.
Kitahara CM, Pfeiffer RM, Sosa JA, et al. Impact of overweight and obesity on US papillary thyroid cancer incidence trends. J Natl Cancer Inst 2020; 112:810–817.
Youssef MR, Reisner ASC, Attia AS, et al. Obesity and the prevention of thyroid cancer: impact of body mass index and weight change on developing thyroid cancer - Pooled results of 24 million cohorts. Oral Oncol 2021; 112:105085.
Shin A, Cho S, Jang D, et al. Body mass index and thyroid cancer risk: a pooled analysis of half a million men and women in the Asia cohort consortium. Thyroid 2022; 32:306–314.
Sorensen SM, Urbute A, Frederiksen K, et al. Prepregnancy body mass index and risk of differentiated thyroid cancer: a prospective cohort study of more than 440,000 Danish women. Thyroid 2023; 33:365–372.
Laaksonen MA, MacInnis RJ, Canfell K, et al. Thyroid cancers potentially preventable by reducing overweight and obesity in Australia: A pooled cohort study. Int J Cancer 2022; 150:1281–1290.
Fang Z, Song M, Lee DH, et al. The role of mendelian randomization studies in deciphering the effect of obesity on cancer. J Natl Cancer Inst 2022; 114:361–371.
Fussey JM, Beaumont RN, Wood AR, et al. Does obesity cause thyroid cancer? A Mendelian randomization study. J Clin Endocrinol Metab 2020; 105:e2398–e2407.
Huang L, Feng X, Yang W, et al. Appraising the effect of potential risk factors on thyroid cancer: a Mendelian randomization study. J Clin Endocrinol Metab 2022; 107:e2783–e2791.
O’Neill RJ, Abd Elwahab S, Kerin MJ, et al. Association of BMI with clinicopathological features of papillary thyroid cancer: a systematic review and meta-analysis. World J Surg 2021; 45:2805–2815.
Economides A, Giannakou K, Mamais I, et al. Association between aggressive clinicopathologic features of papillary thyroid carcinoma and body mass index: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2021; 12:692879.
Cui N, Sun Q, Chen L. A meta-analysis of the influence of body mass index on the clinicopathologic progression of papillary thyroid carcinoma. Medicine (Baltimore) 2021; 100:e26882.
Cao J, Zhu X, Sun Y, et al. Potential impact of body mass index on the clinical outcome of papillary thyroid cancer after high-dose radioactive iodine therapy. Front Endocrinol (Lausanne) 2022; 13:870530.
Dong Z, Liu W, Su F, et al. Association of body mass index with clinicopathological features of papillary thyroid carcinoma: a retrospective study. Endocr Pract 2023; 29:83–88.
Kaliszewski K, Diakowska D, Rzeszutko M, et al. Obesity and overweight are associated with minimal extrathyroidal extension, multifocality and bilaterality of papillary thyroid cancer. J Clin Med 2021; 10:
Wu WX, Feng JW, Ye J, et al. Influence of obesity parameters on different regional patterns of lymph node metastasis in papillary thyroid cancer. Int J Endocrinol 2022; 2022:3797955.
Rahman ST, Pandeya N, Neale RE, et al. Obesity is associated with BRAF(V600E)-mutated thyroid cancer. Thyroid 2020; 30:1518–1527.
Zhang Q, Liu SZ, Zhang Q, et al. Meta-analyses of association between BRAF(V600E) mutation and clinicopathological features of papillary thyroid carcinoma. Cell Physiol Biochem 2016; 38:763–776.
Kim KJ, Kim SG, Tan J, et al. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. Eur J Cancer 2020; 124:161–169.
Engeland A, Tretli S, Akslen LA, et al. Body size and thyroid cancer in two million Norwegian men and women. Br J Cancer 2006; 95:366–370.
Rinaldi S, Lise M, Clavel-Chapelon F, et al. Body size and risk of differentiated thyroid carcinomas: findings from the EPIC study. Int J Cancer 2012; 131:E1004–E1014.
Kim KN, Hwang Y, Kim KH, et al. Adolescent overweight and obesity and the risk of papillary thyroid cancer in adulthood: a large-scale case-control study. Sci Rep 2020; 10:5000.
He Q, Sun H, Li F, et al. Obesity and risk of differentiated thyroid cancer: a large-scale case-control study. Clin Endocrinol (Oxf) 2019; 91:869–878.
Hu MJ, Zhao HH, Li GA, et al. Body mass index and weight gain after middle adulthood are associated with risk of papillary thyroid cancer: a case-control study. Cancer Epidemiol 2021; 75:102039.
Kitahara CM, Gamborg M, Berrington de Gonzalez A, et al. Childhood height and body mass index were associated with risk of adult thyroid cancer in a large cohort study. Cancer Res 2014; 74:235–242.
Hwang Y, Lee KE, Park YJ, et al. Annual average changes in adult obesity as a risk factor for papillary thyroid cancer: a large-scale case-control study. Medicine (Baltimore) 2016; 95:e2893.
Kwon H, Han KD, Park CY. Weight change is significantly associated with risk of thyroid cancer: a nationwide population-based cohort study. Sci Rep 2019; 9:1546.
Avgerinos KI, Spyrou N, Mantzoros CS, et al. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism 2019; 92:121–135.
Jang Y, Kim T, Kim BHS, et al. Association between obesity indexes and thyroid cancer risk in Korean women: nested case-control study. Cancers (Basel) 2022; 14:
Nguyen DN, Kim JH, Kim MK. Association of metabolic health and central obesity with the risk of thyroid cancer: data from the korean genome and epidemiology study. Cancer Epidemiol Biomarkers Prev 2022; 31:543–553.
Li LR, Song JL, Liu HQ, et al. Metabolic syndrome and thyroid cancer: risk, prognosis, and mechanism. Discov Oncol 2023; 14:23.
Li H, Qian J. Association of diabetes mellitus with thyroid cancer risk: a meta-analysis of cohort studies. Medicine (Baltimore) 2017; 96:e8230.
Park JH, Cho HS, Yoon JH. Thyroid cancer in patients with metabolic syndrome or its components: a nationwide population-based cohort study. Cancers (Basel) 2022; 14:
Kwon H, Chang Y, Cho A, et al. Metabolic obesity phenotypes and thyroid cancer risk: a cohort study. Thyroid 2019; 29:349–358.
Franchini F, Palatucci G, Colao A, et al. Obesity and thyroid cancer risk: an update. Int J Environ Res Public Health 2022; 19:
Matrone A, Basolo A, Santini F, et al. Understanding the effect of obesity on papillary thyroid cancer: is there a need for tailored diagnostic and therapeutic management? Expert Rev Endocrinol Metab 2022; 17:475–484.
Zhou Y, Yang Y, Zhou T, et al. Adiponectin and thyroid cancer: insight into the association between adiponectin and obesity. Aging Dis 2021; 12:597–613.
Masone S, Velotti N, Savastano S, et al. Morbid obesity and thyroid cancer rate. a review of literature. J Clin Med 2021; 10:
Cheng SP, Chi CW, Tzen CY, et al. Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery 2010; 147:847–853.
Cheng SP, Liu CL, Hsu YC, et al. Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochem Biophys 2013; 65:203–210.
Celano M, Maggisano V, Lepore SM, et al. Expression of leptin receptor and effects of leptin on papillary thyroid carcinoma cells. Int J Endocrinol 2019; 2019:5031696.
Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, et al. Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metab 2011; 96:E2023–E2028.
Dossus L, Franceschi S, Biessy C, et al. Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: the EPIC study. Int J Cancer 2018; 142:1332–1342.
Kwon H, Park SE, Yun JS, et al. Serum adiponectin and progranulin level in patients with benign thyroid nodule or papillary thyroid cancer. Endocrinol Metab (Seoul) 2020; 35:396–406.
Zhao J, Wen J, Wang S, et al. Association between adipokines and thyroid carcinoma: a meta-analysis of case-control studies. BMC Cancer 2020; 20:788.
Schmidt JA, Allen NE, Almquist M, et al. Insulin-like growth factor-i and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2014; 23:976–985.
Rubio GA, Catanuto P, Glassberg MK, et al. Estrogen receptor subtype expression and regulation is altered in papillary thyroid cancer after menopause. Surgery 2018; 163:143–149.
McLeod DS, Watters KF, Carpenter AD, et al. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 2012; 97:2682–2692.
McLeod DS, Cooper DS, Ladenson PW, et al. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid 2014; 24:35–42.
Wu YY, Cheng SP, Chiou PY, et al. Association between subjective symptoms and obesity and postoperative recurrence in differentiated thyroid cancer: a matched-pair analysis. Sci Rep 2020; 10:3679.